Skip to content
DataLookout
Menu

NCT05169515

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 60 versions: 26 with changes below, 24 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 7 words
    • Primary and study completion moved earlier from Aug 5, 2029 to Apr 30, 2029
    • Study sites: 25 to 24
  2. Minor Primary and study completion moved earlier from Sep 15, 2029 to Aug 5, 2029v59
  3. Minor Enrollment closed, study ongoing
    • Study sites: 26 to 25
    v58
  4. Study Status, Contacts/Locations, Referencesv56
  5. Minor Study sites revised (26)v53
Show 21 earlier versionsHide 21 earlier versions
  1. Minor Study sites revised (26)v50
  2. Notable Primary and study completion dates pushed to Sep 15, 2029v48
  3. Minor Study sites: 27 to 26v38
  4. Notable Primary completion date: Jul 15, 2026 to Mar 7, 2027v37 Show 6 more changesShow less
    • Eligibility criteria expanded, about 136 words
    • Primary endpoints: 3 to 4
    • Study completion date: Jul 15, 2028 to Mar 7, 2029
    • Interventions: CC-220 (Drug), CC-99282 (Drug), IV Glofitamab (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug) to Golcadomide (Drug), IV Glofitamab (Drug), Iberdomide (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug)
    • Secondary endpoints: 10 to 11
    • Study title revised
  5. Notable Primary endpoints: 4 to 3v36 Show 7 more changesShow less
    • Eligibility criteria expanded, about 2 words
    • Enrollment target: 125 to 121
    • Primary completion date: Mar 15, 2027 to Jul 15, 2026
    • Study completion date: Mar 15, 2029 to Jul 15, 2028
    • Interventions: Golcadomide (Drug), IV Glofitamab (Drug), Iberdomide (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug) to CC-220 (Drug), CC-99282 (Drug), IV Glofitamab (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug)
    • Secondary endpoints revised (10)
    • Study title revised
  6. Notable Primary completion date: Jul 15, 2026 to Mar 15, 2027v35 Show 7 more changesShow less
    • Primary endpoints: 3 to 4
    • Eligibility criteria shortened, about 2 words
    • Enrollment target: 121 to 125
    • Study completion date: Jul 15, 2028 to Mar 15, 2029
    • Interventions: CC-220 (Drug), CC-99282 (Drug), IV Glofitamab (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug) to Golcadomide (Drug), IV Glofitamab (Drug), Iberdomide (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug)
    • Secondary endpoints revised (10)
    • Study title revised
  7. Minor Site details revised at 1 of 27 sitesv34
  8. Minor Study sites: 25 to 27v31
  9. Minor Study sites: 24 to 25v27
  10. Minor Study sites: 23 to 24v26
  11. Minor Study sites: 21 to 23v25
  12. Minor Study sites: 19 to 21v24
  13. Notable Primary completion date: Apr 15, 2025 to Jul 15, 2026
    • Eligibility criteria expanded, about 33 words
    • Study completion date: Apr 15, 2027 to Jul 15, 2028
    • Secondary endpoints: 21 to 10
    v22
  14. Minor Enrollment target: 112 to 121v21
  15. Minor Study sites: 18 to 19v20
  16. Minor Study sites: 17 to 18v18
  17. Minor Study sites: 14 to 17v17
  18. Notable Eligibility criteria expanded, about 18 words
    • Study sites: 10 to 14
    v14
  19. Minor Study sites: 7 to 10v13
  20. Minor Study sites: 5 to 7
    • Start date changed from estimate of Oct 15, 2022 to Oct 26, 2022
    v12
  21. Notable Start date: Sep 15, 2022 to Oct 15, 2022
    • Study sites: 3 to 5
    v11
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of participants with dose-limiting toxicities (DLTs) [dose escalation]
Timeframe: Until 90 days after the final dose of study treatment
Percentage of participants with adverse events [all cohorts]
Timeframe: Until 90 days after the final dose of study treatment
Best overall response rate (ORR), defined as the proportion of participants whose best overall response is a partial response (PR) or a complete response (CR) during the study, as determined by the investigator using Lugano 2014 criteria [dose expansion]
Timeframe: Up to 2 years after start of primary study treatment
Tolerability, as assessed by the incidence of dose interruptions, dose reductions, dose intensity, and treatment discontinuation [dose escalation]
Timeframe: Until 90 days after the final dose of study treatment

Secondary (11)

Best CR rate, defined as the proportion of participants whose best overall response is a CR during the study, as determined by the investigator using Lugano 2014 criteria [all cohorts]
Best ORR (CR or PR at any time) on study as determined by the investigator using Lugano 2014 criteria [dose escalation]
Duration of response (DOR) as determined by the investigator using Lugano 2014 criteria [all cohorts]
Progression-free survival (PFS) as determined by the investigator using Lugano 2014 criteria [dose expansion]
Event-free survival (EFS) as determined by the investigator using Lugano 2014 criteria [dose expansion]
Show 6 moreShow less
Overall survival (OS) [dose expansion]
Percentage of participants with adverse events [dose expansion]
Serum concentration of subcutaneous (SC) mosunetuzumab [all cohorts]
Serum concentration of intravenous (IV) glofitamab [all cohorts]
Serum concentration of CC-220 and CC-99282 (CELMoDs) [all cohorts]
Tolerability, as assessed by the incidence of dose interruptions, dose reductions, dose intensity, and treatment discontinuation [dose expansion]

Arms and interventions

Arm 1Experimental

Participants will receive subcutaneous (SC) mosunetuzumab + CC-220 (dose escalation only) or SC mosunetuzumab + CC-99282.

Arm 2Experimental

Participants will receive intravenous (IV) glofitamab + CC-99282.

Drugs: SC Mosunetuzumab, IV Glofitamab, Iberdomide, Golcadomide, Obinutuzumab, Tocilizumab

Sites

24 sites in 5 countries

Spain 6, United States 6, Israel 5, United Kingdom 4, Italy 3